The Gene Variants Behind MCS: What CYP2D6, GSTM1, GSTT1, GSTP1, and MTHFR Mean for You

Every person with MCS eventually asks the same question: why me? Two people work in the same building, breathe the same air, eat the same food. One develops MCS. The other does not. They were exposed to the same chemicals. Why did one person's body sensitize and the other's did not?

Part of the answer may be in your genes — a set of common variants that shape how your body processes chemicals. These are not rare disease genes; they are population variants carried by a substantial portion of people, and most people who carry them never develop MCS. What the evidence supports is susceptibility, not cause: inherited differences appear to be part of why the same exposure sensitizes one person and not another. What it does not support is the older claim that MCS is a failure to clear or detoxify chemicals — the Toronto finding described below points to faster metabolism, not slower.

How does the body's detoxification system process chemicals — and where does it break down?

Before the individual genes make sense, it helps to understand the system they belong to. The body processes foreign chemicals — xenobiotics, the technical term for drugs, environmental chemicals, pesticides, solvents, and metabolic byproducts — in two main phases.

Phase 1 detoxification, primarily in the liver, uses cytochrome P450 enzymes to chemically modify xenobiotics — breaking them into intermediate compounds that can be processed further. CYP2D6 is one of the most important Phase 1 enzymes for this.

Phase 2 detoxification takes those intermediate compounds and conjugates them — attaches molecules that make them water-soluble so they can be excreted in urine or bile. Glutathione S-transferases (GSTM1, GSTT1, GSTP1) are the key Phase 2 enzymes for this. Glutathione itself is the molecule they use.

Methylation — the process supported by MTHFR and dependent on B12 and folate — handles the downstream processing of many toxin metabolites, neurotransmitters, and cellular waste products. Without adequate methylation, the breakdown products of Phase 1 and Phase 2 processing cannot be fully cleared.

The chain is: Phase 1 modifies the chemical → Phase 2 conjugates it for excretion → Methylation completes downstream processing. Variants in these genes change how the chain runs. Whether that matters for MCS is the open question: the “impaired detoxification” model treated slower clearance as the cause of MCS, and the best-known MCS genetic finding found the opposite direction. Reduced glutathione has been measured in some MCS cohorts (De Luca 2010; a 2025 pilot), but that is a measured state, not a genotype and not a proven cause.

Is there a genetic basis for MCS itself, separate from CIRS?

The evidence is real but incomplete. Multiple independent studies have found chemically sensitive people to differ genetically from comparison groups, though not always in the same genes.

The Toronto 2004 case-control study of 203 women with MCS and 162 controls found significantly higher odds of MCS in those carrying the active and rapid variants of CYP2D6 (OR 3.36) and NAT2 (OR 4.14) — faster metabolism, not slower. PON1 was examined without a clear signal, and the finding has not been consistently replicated since. The companion laboratory paper from the same group (Baines 2004; 223 patients, 194 controls) found routine biochemistry unremarkable. A post-hoc look at people carrying both found an OR of 18.7 — but the study's own authors flagged that this specific comparison was not part of the original study design and urged caution pending replication, which is worth taking at face value rather than treating the 18.7 figure as a settled finding. A separate 2007 study of 521 people reporting chemical sensitivity (a broader, not formally MCS-diagnosed population) found significantly higher odds among those with homozygous GSTM1 deletion (OR 2.08) and GSTT1 deletion (OR 2.80) — the finding referenced in the box above. A Japanese study of 324 workers found a distinct signal in SOD2, a gene involved in antioxidant defense, with odds ratios around 4.3–4.5 in the most chemically sensitive group — small and hypothesis-generating, like the SLC finding below. The cleanest gene–environment result in the field is not an MCS study at all: in Gulf War veterans, PON1 genotype interacted with recorded exposure to predict who became ill, which is what a susceptibility gene is expected to do.

Some of these findings haven't replicated in later studies — the 2025 whole-exome study referenced throughout this page found no CYP2D6 signal, for instance, and GSTM1/GSTT1 were tested but not significant in the same small sample where SLC-family genes stood out (below). That inconsistency is worth stating plainly rather than glossing over. But it most likely reflects that MCS is heterogeneous, not that genetics is absent from the picture: different people may cross the same susceptibility threshold through different combinations of inherited variants in detoxification, oxidative-stress, or — per that same small 2025 study — neurotransmitter-transport genes.

That 2025 whole-exome study (six MCS patients, five controls — genuinely pilot-scale, not a population study) found rare homozygous variants in the SLC gene superfamily in every affected patient and none of the controls, a statistically significant imbalance even at that small sample size. SLC genes govern transport of neurotransmitters and other molecules across cell membranes. The finding is far too small to establish a diagnostic signature on its own, but it points toward biological mechanisms beyond the classic detoxification-gene story.

Family clustering fits the same picture. Chemical sensitivity and related multisystem illness repeatedly appear within families, while people sharing the same home or workplace can have very different outcomes — one person becomes profoundly ill, a spouse sharing much of the same environment does not. Shared environment explains part of that pattern; it does not by itself explain why genetically related people show recurring susceptibility while others exposed alongside them stay well. A large Japanese cohort study found maternal chemical intolerance associated with allergic and respiratory conditions in their young children, and the study authors concluded that both “inherent physical constitution” and shared environment likely contribute — consistent with, though not proof of, a genetic component.

The honest summary: inherited biological susceptibility appears to be part of the MCS story. What has not been established is a single MCS gene or a single genetic test that identifies who will become sensitized. Different combinations of variants across detoxification, oxidative-stress, immune, and neural-signaling pathways may each create part of the vulnerable terrain that a sufficiently large chemical exposure then activates.

What does CYP2D6 do, and what does the MCS evidence actually show?

How common: CYP2D6 metabolizer status runs on a spectrum — poor, intermediate, extensive (normal), and ultrarapid — determined by the specific combination of alleles you inherit from each parent, not by any single genetic marker.

A single “reduced-function SNP” on a consumer DNA report does not by itself establish your metabolizer status: you inherit one CYP2D6 copy from each parent, one copy could be reduced-function while the other is normal, and CYP2D6 can also be deleted, duplicated, or rearranged — details a single-SNP readout misses entirely. A full diplotype, copy-number result, and calculated activity score are what actually determine your phenotype.

What it does: CYP2D6 is one of the most well-studied Phase 1 detox enzymes in the liver and brain, responsible for metabolizing roughly 25% of all commonly prescribed drugs — its best-established role by far. It also processes some pesticides and environmental chemicals, though this is a less centrally confirmed part of its function: CPIC, the clinical authority on CYP2D6, states plainly that CYP2D6 variation has not been consistently linked to any disease or condition independent of specific drug responses. CYP2D6’s role in MCS specifically should be read with that in mind.

MCS connection: The genetic evidence here is more mixed than for GSTM1/GSTT1. A 2004 case-control study of 203 women with MCS found significantly higher odds of MCS in those with fast (extensive) CYP2D6 metabolism and fast-acetylating NAT2 genotypes — women with the fast form of both were roughly eighteen times more likely to report chemical intolerance. But the newest and most direct MCS genetic study (2025, whole-exome sequencing) did not replicate this: it found slightly more rare CYP2D6 variants in its control group than its patient group, and its authors did not treat CYP2D6 as a supported MCS candidate gene. Taken together, CYP2D6 is worth testing and discussing with a knowledgeable practitioner, especially given its established role in drug metabolism — but its specific role in MCS is not settled the way the GSTM1/GSTT1 finding is. Treat a CYP2D6 result as one data point, not an explanation for your MCS.

Testing: Clinical pharmacogenomic testing for CYP2D6 reports both inherited alleles (your full diplotype) plus a calculated activity score — this is what you actually need, not a single SNP. Raw consumer DNA data (23andMe, AncestryDNA) can be run through pharmacogenomics interpretation tools, but these frequently flag isolated SNPs without confirming the full diplotype or checking for copy-number variation, which can produce a misleading “poor metabolizer” read. If CYP2D6 testing matters to you — most directly relevant for medication dosing — ask specifically for the complete diplotype, star alleles, copy-number result, and activity score, not a single-marker readout.

What is the GSTM1 null genotype and how does it affect chemical processing in MCS patients?

How common: The GSTM1 null genotype — the gene is completely deleted, producing no enzyme at all — occurs in approximately 40–60% of people depending on ethnic background. This is genuinely common. Nearly half the population carries this deletion.

What it does: GSTM1 is a Phase 2 detoxification enzyme that uses glutathione to conjugate and neutralize a wide range of xenobiotics, carcinogens, and oxidative stress byproducts. When GSTM1 is present, glutathione binds to these substances and makes them water-soluble for excretion. When GSTM1 is null — deleted — this entire detox pathway is absent. Not just reduced: absent. The body must rely on other glutathione S-transferase isoforms to compensate, and they cannot fully cover the gap.

MCS connection: A 2007 study of over 500 people found MCS significantly more common in those carrying GSTM1-null and GSTT1-null genotypes — the same enzymes described above. That study drew on a survey population reporting chemical sensitivity, not a consensus-defined MCS cohort, and it reports an association, not a mechanism. The proposed explanation — that chemicals GSTM1 normally handles stay active longer in a null individual — is plausible biochemistry that has not been shown to cause MCS; the 2025 whole-exome study tested GSTM1/GSTT1 and found no signal in its small sample.

Testing: GSTM1 can be tested through standard genetic panels, 23andMe raw data analysis, or functional medicine genetic testing. The result is binary: either you have the gene or you do not.

What do GSTT1 and GSTP1 do, and how do they compound detoxification impairment?

The GSTT1 null genotype (10–20% of Europeans, higher elsewhere) means the enzyme is completely absent. GSTT1 processes halogenated compounds, ethylene oxide, and some organochlorines. Carrying both GSTM1 and GSTT1 null creates a compounded Phase 2 deficit — two pathways missing.

GSTP1: Unlike GSTM1 and GSTT1, GSTP1 is rarely deleted entirely — instead, it carries a common polymorphism (Ile105Val) that reduces enzyme efficiency rather than eliminating it. GSTP1 is particularly important in the brain and lungs, where it detoxifies reactive oxygen species and electrophilic compounds. The Ile105Val variant is present in approximately 30–40% of people and has been specifically associated with increased susceptibility to chemical-induced neurological damage. For MCS patients whose symptoms include neurological components — brain fog, cognitive slowing, sensory amplification — GSTP1 variant status may be particularly relevant.

How does MTHFR affect chemical sensitivity, and what does the methylation pathway have to do with MCS?

How common: The two most common MTHFR variants are C677T (present in approximately 40% of people in heterozygous form, 10–15% in homozygous form) and A1298C (present in approximately 30% heterozygous).

Homozygous C677T reduces MTHFR enzyme activity by approximately 70%. Compound heterozygous (one copy of each variant) reduces activity by approximately 50%.

What it does: MTHFR converts folate into 5-methyltetrahydrofolate (5-MTHF), the active form the body uses for methylation. Methylation is the process of adding a methyl group (CH3) to molecules — it is fundamental to DNA repair, neurotransmitter synthesis, detoxification of heavy metals and certain chemicals, immune cell function, and the recycling of glutathione. When MTHFR function is impaired, methylation throughout the body runs at reduced capacity. Homocysteine accumulates (a marker of methylation impairment detectable by standard blood test). Heavy metals like mercury and arsenic, which require methylation for excretion, are retained longer.

MCS connection: MTHFR impairment is not specific to MCS — it is a general population variant associated with a range of health conditions. Its relevance to MCS is primarily in three areas: (1) reduced glutathione recycling capacity compounds the Phase 2 detox deficit from GSTM1/GSTT1/GSTP1 variants; (2) impaired neurotransmitter synthesis and methylation of brain chemistry affects neurological sensitivity; (3) methylation-dependent excretion of heavy metals is slower. None of these has been tested in an MCS cohort.

Testing: MTHFR genetic testing is widely available through 23andMe, standard labs, and functional medicine providers. Blood homocysteine is a functional marker — elevated homocysteine (above approximately 10–12 μmol/L) indicates impaired methylation in practice, regardless of genetic test results. Functional treatment typically involves 5-MTHF (methylfolate) supplementation and methylcobalamin (methylB12), under practitioner guidance.

Can you test for these gene variants, and should you?

Yes, all five variants are testable. The practical question is how to do it and what to do with the results.

Consumer genetic testing (23andMe, AncestryDNA): Raw data from these platforms includes SNP data that covers most of these variants. The raw data itself is not interpreted — you need a separate tool to analyze it. Genetic Genie, Promethease, and Sterling's App are among the tools that can analyze 23andMe raw data for MTHFR, GSTM1/GSTT1/GSTP1, and other variants relevant to detox function. These tools vary in quality and should be used as starting points, not definitive clinical reports.

Clinical pharmacogenomic testing: For CYP2D6 specifically, clinical pharmacogenomic tests ordered through a physician provide definitive metabolizer status classification. These are increasingly covered by insurance, particularly for patients on medications that CYP2D6 processes.

Functional medicine panels: Practitioners trained in environmental medicine and functional medicine can order comprehensive detox gene panels that include all five variants discussed here, along with clinical interpretation. Organizations like ISEAI (International Society for Environmentally Acquired Illness) maintain a directory of practitioners familiar with MCS and chemical sensitivity.

What can you do differently if you carry these gene variants?

Understanding your gene variants does not change the fundamentals of MCS management — reducing exposure remains the one strategy supported by every source we have. What it does change is how you can target your support interventions more precisely.

For CYP2D6 results: The clearest, best-established use of a CYP2D6 result is medication management — many common medications are CYP2D6 substrates and may need dose adjustment regardless of what your MCS looks like. If your full diplotype shows fast metabolism, supporting Phase 2 conjugation capacity (see the GSTM1/GSTT1 notes below) is a reasonable precaution given the proposed mechanism above, but treat it as a precaution, not a confirmed MCS explanation.

For GSTM1/GSTT1 null: Supporting glutathione production and availability becomes more important because the enzymes that use glutathione are absent or reduced. N-acetylcysteine (NAC), which is a glutathione precursor, and liposomal or nebulized glutathione (forms that bypass the gut degradation issue with oral glutathione) are among the approaches used by practitioners in this population. See the separate Supporting Your Body guide for support strategies in depth.

For GSTP1 variants: Cruciferous vegetables (broccoli, Brussels sprouts, cabbage) upregulate glutathione S-transferase enzymes — the dietary approach to partially compensating for reduced enzyme activity. This is not a cure, but it is a measurable dietary intervention with documented effects on GST activity.

For MTHFR variants: 5-MTHF (methylfolate) replaces standard folic acid supplementation — people with MTHFR C677T cannot efficiently convert standard folate to its active form. Methylcobalamin replaces cyanocobalamin for B12. Blood homocysteine provides a functional check on whether methylation has normalized. Any supplementation protocol should be supervised by a practitioner familiar with MTHFR and chemical sensitivity, as some people experience paradoxical reactions to methyl donors.

For all variants: The most fundamental intervention remains reducing exposure — source elimination from your home and daily environment. See the Home Sources guide for where to start identifying what your home is releasing. Gene variants may be part of your susceptibility. Reducing exposures is what the evidence supports.